FDA WARNING_LETTER - eDrugstore - August 31, 2025

The FDA issued a warning letter to eDrugstore, located at 5801 S. McClintock Drive, Suite 107, Tempe, AZ, on September 9, 2025, following a review of their website in August 2025. The FDA identified that eDrugstore"s website offers compounded drug products, including tirzepatide, with claims that are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA). These claims suggest that the compounded drugs are equivalent to FDA-approved products, which they are not, resulting in the misbranding of these products.

The regulatory framework cited includes sections 502(a), 502(bb), and 301(a) of the FDCA, which address misbranding and the introduction of such products into interstate commerce. The FDA requires eDrugstore to take immediate corrective actions, including ceasing the use of misleading language and ensuring compliance with federal law. The company must respond within 15 working days, detailing the steps taken to rectify the violations and prevent recurrence. Failure to comply may lead to legal actions such as seizure or injunction.

eDrugstore is advised to provide a written response to the Office of Compounding Quality and Compliance, including documentation of corrective measures. If eDrugstore believes their products are compliant, they must provide supporting information. Non-compliance could result in further regulatory actions, including notifying foreign regulatory bodies if applicable.